Axitinib

Generic Name: Axitinib

Brand Names: Inlyta, Axitinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₈N_₄OS

CAS Number: 319460-85-0

Unique Ingredient Identifier: C9LVQ0YUXG

Background: Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...

Indication: Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Thyroid cancer

Associated Therapies: First Line Chemotherapy

Clinical Trials

Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma

Phase 2

Completed

Conditions: Recurrent ACC, metastaticACC, Unreaectable ACC

Interventions: Other: Observation
Drug: Axitinib

First Posted Date: 2016-08-08

Last Posted Date: 2024-05-29

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 60

Registration Number: NCT02859012

Locations: 🇰🇷
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of

Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14

Phase 2

Completed

Conditions: Salivary Gland Cancers

Interventions: Drug: Axitinib

First Posted Date: 2016-08-05

Last Posted Date: 2019-08-30

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 26

Registration Number: NCT02857712

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Phase 3

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Biological: Pembrolizumab
Drug: Sunitinib
Drug: Axitinib

First Posted Date: 2016-08-02

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 861

Registration Number: NCT02853331

The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC

Phase 1

Completed

Conditions: Advanced Hepatocellular Carcinoma (HCC)

Interventions: Drug: Axitinib
Radiation: Radiation

First Posted Date: 2016-06-27

Last Posted Date: 2019-09-23

Lead Sponsor: Shin Kong Wu Ho-Su Memorial Hospital

Target Recruit Count: 9

Registration Number: NCT02814461

Locations: 🇨🇳
Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML)
Chronic Phase Phase Chronic Myelogenous Leukemia (CML)
Blast Phase Chronic Myelogenous Leukemia (CML)
Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)

Interventions: Drug: Axitinib
Drug: Bosutinib
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-05-25

Last Posted Date: 2020-11-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT02782403

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Expansion Trial for Axitinib In Head And Neck Cancer

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Axitinib

First Posted Date: 2016-05-05

Last Posted Date: 2021-05-05

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 29

Registration Number: NCT02762513

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors

Phase 2

Completed

Conditions: Carcinoma, Renal Cell
Clear Cell Renal Cell Carcinoma

Interventions: Drug: axitinib

First Posted Date: 2016-03-07

Last Posted Date: 2019-10-22

Lead Sponsor: Kidney Cancer Research Bureau

Target Recruit Count: 21

Registration Number: NCT02700568

Locations: 🇷🇺
Usynin Evgeny Anatolievich, Tomsk, Russian Federation
🇷🇺
Mikhailova Nadezhda Vasilievna, Kazan, Russian Federation
🇷🇺
Ivannikov Andrey Andreyevich, Tambov, Russian Federation

and more 12 locations

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

Phase 1

Completed

Conditions: Clear Cell Renal Cell Carcinoma

Interventions: Drug: X4P-001
Drug: axitinib

First Posted Date: 2016-01-29

Last Posted Date: 2024-10-03

Lead Sponsor: X4 Pharmaceuticals

Target Recruit Count: 74

Registration Number: NCT02667886

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: AGS-16C3F
Drug: Axitinib

First Posted Date: 2015-12-24

Last Posted Date: 2024-11-18

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 133

Registration Number: NCT02639182

Locations: 🇺🇸
Site US01020, Los Angeles, California, United States
🇺🇸
Site US01004, Ann Arbor, Michigan, United States
🇺🇸
Site US01008, La Jolla, California, United States

and more 23 locations

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

First Posted Date: 2015-12-23

Last Posted Date: 2020-03-19

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 90

Registration Number: NCT02638428

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy